The condition can be tricky though, since older adults’ bladders are often colonized with bacteria that will show in a test but are not causing symptoms.
The €4.5 million ($4.2 million) effort is led by researchers from Sweden's Karolinska Institute and aims to deliver lateral flow tests and point-of-care devices.
The following is a summary of “Evaluating the use of Uromune® autovaccine in recurrent urinary tract infections: a pilot unicenter retrospective study in Reus, Spain,” published in the January 2025 ...